These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 19584240

  • 1. D,L-Sulforaphane causes transcriptional repression of androgen receptor in human prostate cancer cells.
    Kim SH, Singh SV.
    Mol Cancer Ther; 2009 Jul; 8(7):1946-54. PubMed ID: 19584240
    [Abstract] [Full Text] [Related]

  • 2. Sulforaphane increases the efficacy of anti-androgens by rapidly decreasing androgen receptor levels in prostate cancer cells.
    Khurana N, Talwar S, Chandra PK, Sharma P, Abdel-Mageed AB, Mondal D, Sikka SC.
    Int J Oncol; 2016 Oct; 49(4):1609-19. PubMed ID: 27499349
    [Abstract] [Full Text] [Related]

  • 3. Transcriptional repression and inhibition of nuclear translocation of androgen receptor by diallyl trisulfide in human prostate cancer cells.
    Stan SD, Singh SV.
    Clin Cancer Res; 2009 Aug 01; 15(15):4895-903. PubMed ID: 19622577
    [Abstract] [Full Text] [Related]

  • 4. Repression of androgen receptor in prostate cancer cells by phenethyl isothiocyanate.
    Wang LG, Liu XM, Chiao JW.
    Carcinogenesis; 2006 Oct 01; 27(10):2124-32. PubMed ID: 16704988
    [Abstract] [Full Text] [Related]

  • 5. D,L-Sulforaphane-induced cell death in human prostate cancer cells is regulated by inhibitor of apoptosis family proteins and Apaf-1.
    Choi S, Lew KL, Xiao H, Herman-Antosiewicz A, Xiao D, Brown CK, Singh SV.
    Carcinogenesis; 2007 Jan 01; 28(1):151-62. PubMed ID: 16920735
    [Abstract] [Full Text] [Related]

  • 6. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
    Long BJ, Grigoryev DN, Nnane IP, Liu Y, Ling YZ, Brodie AM.
    Cancer Res; 2000 Dec 01; 60(23):6630-40. PubMed ID: 11118046
    [Abstract] [Full Text] [Related]

  • 7. Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells.
    Bhattacharyya RS, Krishnan AV, Swami S, Feldman D.
    Mol Cancer Ther; 2006 Jun 01; 5(6):1539-49. PubMed ID: 16818513
    [Abstract] [Full Text] [Related]

  • 8. Notch activation is dispensable for D, L-sulforaphane-mediated inhibition of human prostate cancer cell migration.
    Hahm ER, Chandra-Kuntal K, Desai D, Amin S, Singh SV.
    PLoS One; 2012 Jun 01; 7(9):e44957. PubMed ID: 22970326
    [Abstract] [Full Text] [Related]

  • 9. Down-regulation of androgen receptor by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells.
    Bhuiyan MM, Li Y, Banerjee S, Ahmed F, Wang Z, Ali S, Sarkar FH.
    Cancer Res; 2006 Oct 15; 66(20):10064-72. PubMed ID: 17047070
    [Abstract] [Full Text] [Related]

  • 10. Sulforaphane and its metabolite mediate growth arrest and apoptosis in human prostate cancer cells.
    Chiao JW, Chung FL, Kancherla R, Ahmed T, Mittelman A, Conaway CC.
    Int J Oncol; 2002 Mar 15; 20(3):631-6. PubMed ID: 11836580
    [Abstract] [Full Text] [Related]

  • 11. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens.
    Waltering KK, Helenius MA, Sahu B, Manni V, Linja MJ, Jänne OA, Visakorpi T.
    Cancer Res; 2009 Oct 15; 69(20):8141-9. PubMed ID: 19808968
    [Abstract] [Full Text] [Related]

  • 12. Sulforaphane inhibits constitutive and interleukin-6-induced activation of signal transducer and activator of transcription 3 in prostate cancer cells.
    Hahm ER, Singh SV.
    Cancer Prev Res (Phila); 2010 Apr 15; 3(4):484-94. PubMed ID: 20233902
    [Abstract] [Full Text] [Related]

  • 13. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms.
    Tepper CG, Vinall RL, Wee CB, Xue L, Shi XB, Burich R, Mack PC, de Vere White RW.
    Prostate; 2007 Apr 01; 67(5):521-35. PubMed ID: 17252539
    [Abstract] [Full Text] [Related]

  • 14. Prohibitin and the SWI/SNF ATPase subunit BRG1 are required for effective androgen antagonist-mediated transcriptional repression of androgen receptor-regulated genes.
    Dai Y, Ngo D, Jacob J, Forman LW, Faller DV.
    Carcinogenesis; 2008 Sep 01; 29(9):1725-33. PubMed ID: 18487222
    [Abstract] [Full Text] [Related]

  • 15. Induction of p21 protein protects against sulforaphane-induced mitotic arrest in LNCaP human prostate cancer cell line.
    Herman-Antosiewicz A, Xiao H, Lew KL, Singh SV.
    Mol Cancer Ther; 2007 May 01; 6(5):1673-81. PubMed ID: 17513615
    [Abstract] [Full Text] [Related]

  • 16. Indole-3-carbinol inhibition of androgen receptor expression and downregulation of androgen responsiveness in human prostate cancer cells.
    Hsu JC, Zhang J, Dev A, Wing A, Bjeldanes LF, Firestone GL.
    Carcinogenesis; 2005 Nov 01; 26(11):1896-904. PubMed ID: 15958518
    [Abstract] [Full Text] [Related]

  • 17. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H.
    Br J Cancer; 1999 Sep 01; 81(2):242-51. PubMed ID: 10496349
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer.
    Gan L, Chen S, Wang Y, Watahiki A, Bohrer L, Sun Z, Wang Y, Huang H.
    Cancer Res; 2009 Nov 01; 69(21):8386-94. PubMed ID: 19826044
    [Abstract] [Full Text] [Related]

  • 19. Androgen receptor as a regulator of ZEB2 expression and its implications in epithelial-to-mesenchymal transition in prostate cancer.
    Jacob S, Nayak S, Fernandes G, Barai RS, Menon S, Chaudhari UK, Kholkute SD, Sachdeva G.
    Endocr Relat Cancer; 2014 Jun 01; 21(3):473-86. PubMed ID: 24812058
    [Abstract] [Full Text] [Related]

  • 20. Lupeol, a novel androgen receptor inhibitor: implications in prostate cancer therapy.
    Siddique HR, Mishra SK, Karnes RJ, Saleem M.
    Clin Cancer Res; 2011 Aug 15; 17(16):5379-91. PubMed ID: 21712449
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.